



FOR IMMEDIATE RELEASE

Frontier BioStrategy Launches as Integrated Strategic Advisory for Biological Technologies

New advisory firm combines regulatory architecture, commercial strategy, and product development governance under a single senior engagement, addressing a fragmentation problem the agricultural biologicals sector has long ignored.

RALEIGH, NC — May 13, 2026 — Frontier BioStrategy LLC, an integrated strategic advisory firm for biological technologies, launched yesterday. Founded by three industry veterans with more than 60 years of combined executive experience across agrochemicals, biologicals, and agricultural R&D, the firm offers regulatory architecture, commercial strategy, and product development governance through a single senior advisory engagement, purpose-built for biological technologies navigating complex and evolving regulatory landscapes.

The agricultural biologicals sector does not have a strategy or a science problem. It has a fragmentation problem. Regulatory advisors typically lack understanding of commercial timelines. Commercial strategists underestimate regulatory complexity. Product development leaders are often hired full-time before companies can afford them. Frontier BioStrategy was built to eliminate that gap by integrating all three disciplines under a single senior engagement model.

The firm's three principals (Matthew Orr, Ben Cicora, and Marco Toapanta) bring current, hands-on experience in biological agriculture, most recently through a successful platform acquisition. There are no junior handoffs and no siloed advice. The expertise the firm brings is not archival; it is the regulatory, commercial, and development reality clients are navigating right now.

“Most biological technology companies do not fail because the science is bad. They fail because the path from breakthrough to market was never architected as a single system: regulatory, commercial, and development in lockstep. We have just spent the last several years inside that reality. The integration we now offer clients is the operating model we proved before we offered it.”

— Ben Cicora, Co-Founder and Managing Director, Commercial, Frontier BioStrategy

Frontier BioStrategy works with early-stage biological technology companies (Seed through Series B), growth-stage firms scaling internationally, and venture capital and private equity investors evaluating biological assets. The firm's primary focus is on emerging categories with evolving regulatory pathways: RNAi and dsRNA, gene-edited traits, peptide-based bioactives, novel mode-of-action biopesticides, and next-generation biostimulants.

About Frontier BioStrategy

Frontier BioStrategy LLC is an integrated strategic advisory firm for biological technologies, founded in 2026 and based in Raleigh, North Carolina. The firm provides regulatory architecture, commercial strategy, and product development governance under a single senior advisory engagement. Its principals (Matthew Orr, Ben Cicora, and Marco Toapanta) bring combined experience spanning more than 60 years across agrochemicals, biologicals, and agricultural R&D at the executive level.

Media Contact

Frontier BioStrategy LLC
contact@frontierbiostrategy.com
www.frontierbiostrategy.com

###